Abstract:ABSTRACT Carbapenem-resistant Klebsiella pneumoniae (CRKP) and Escherichia coli (CREC) are frequently detected in clinical settings, restricting the use of carbapenems. Therefore, there is an urgent need for new antimicrobial strategies to address infections caused by CRKP and CREC. This study investigated the antibacterial, anti-biofilm, and anti-inflammatory effects of the cationic antimicrobial peptide Hs02, along with its potential antimicrobial mechanisms against CRKP and CREC. The results revealed that Hs02 had a low minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) against CRKP and CREC, effectively eliminating the bacteria within 30 min. Moreover, Hs02 significantly prevents biofilm formation and disrupts the established biofilms. Further mechanistic studies demonstrated that Hs02 specifically targeted and bound to bacterial outer membrane lipopolysaccharides (LPS), disrupted membrane permeability and integrity, which led to intracellular reactive oxygen species (ROS) accumulation. Furthermore, Hs02 neutralized LPS, thereby suppressing the production of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in murine macrophage RAW 264.7 cells. In vitro , hemolysis and cytotoxicity assays confirmed Hs02’s safety at the tested concentrations and proved that Hs02 improved the survival rate of Galleria mellonella larvae. In conclusion, the findings suggest that Hs02’s interaction with LPS and the resulting disruption of membrane integrity may be key factors driving its rapid bactericidal and anti-inflammatory effects. IMPORTANCE Eukaryotic antimicrobial peptides are typically amphipathic peptides consisting of approximately 50 amino acids. Many macromolecular proteins in our body contain polypeptide sequences that show characteristics similar to those of antimicrobial peptides. The present research highlights a gap in the current literature regarding the mechanisms by which the intragenic antimicrobial peptide Hs02, derived from human proteins, exerts its rapid bactericidal and anti-inflammatory effects. The findings demonstrate that lipopolysaccharide (LPS) is a key target of Hs02’s antimicrobial activity and that its ability to neutralize LPS is crucial for its anti-inflammatory effects.

Cationic antimicrobial peptide LL-37 and it's potential therapeutic role in sepsis

Research Advances of Cationic Antimicrobial Peptides in the Immune Response in Sepsis

Turing cationic antimicrobial peptide KR-12 into Self-assembled nanobiotics with potent bacterial killing and LPS neutralizing activities

Defensins and sepsis.

Defensins and Sepsis

Turning cationic antimicrobial peptide KR-12 into self-assembled nanobiotics with potent bacterial killing and LPS neutralizing activities

A Pro-Healing Short-Chain Antimicrobial Peptide That Inhibits Sepsis

Protective Effect of Ginsenosides Rg1 and Re on Lipopolysaccharide-Induced Sepsis by Competitive Binding to Toll-like Receptor 4.

LL-37: Structures, Antimicrobial Activity, and Influence on Amyloid-Related Diseases

Protective Role of Ilc2 in Sepsis-Induced Acute Lung Injury

The LL-37 antimicrobial peptide as a treatment for systematic infection of Acinetobacter baumannii in a mouse model.

ICAM-1-targeted and Antibacterial Peptide Modified Polymeric Nanoparticles for Specific Combating Sepsis

Antimicrobial peptide Hs02 with rapid bactericidal, anti-biofilm, and anti-inflammatory activity against carbapenem-resistant Klebsiella pneumoniae and Escherichia coli

Identification of heptapeptides targeting a lethal bacterial strain in septic mice through an integrative approach

Cath-HG improves the survival rates and symptoms in LPS-induced septic mice due to its multifunctional properties

Repolarization of Inflammation-Associated Macrophages by Dual Drug-Loaded Liposomes for Acute Lung Sepsis Antibacterial and Anti-inflammatory Therapy

Antimicrobial peptide nanoparticles coated with macrophage cell membrane for targeted antimicrobial therapy of sepsis

Molecular Dynamics Simulations of Human Antimicrobial Peptide LL-37 in Model POPC and POPG Lipid Bilayers

Antimicrobial Peptide Cathelicidin-BF Prevents Intestinal Barrier Dysfunction in a Mouse Model of Endotoxemia.

Antibacterial Fusion Protein BPI21/LL-37 Modification Enhances the Therapeutic Efficacy of hUC-MSCs in Sepsis

Antimicrobial Peptide MPX with Broad-Spectrum Bactericidal Activity Promotes Proper Abscess Formation and Relieves Skin Inflammation